Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Verde et al. Molecular Mechanisms of Protein Aggregation in ALS-FTD: Focus on TDP-43 and Cellular Protective Responses. <i>Cells</i> 2025, <i>14</i>, 680.

Cells·2026
Same author

Longitudinal CSF and Serum Biomarker Dynamics in Tofersen-Treated <i>SOD1</i>-ALS: A Real-World Multicentre Cohort Study.

International journal of molecular sciences·2026
Same author

Green space exposure and risk of amyotrophic lateral sclerosis: a population-based case-control study in Northern Italy.

Environmental health : a global access science source·2026
Same author

Unilateral Primary Angiitis of the Central Nervous System (PACNS): a case report of unusual radiological presentation.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Circulating Serum Cell-Free Mitochondrial DNA in Amyotrophic Lateral Sclerosis.

Cells·2025
Same author

Most prominent challenges in translational neuroscience and strategic solutions to bridge the gaps: Perspectives from an editorial board interrogation.

Exploration of neuroscience·2025

Related Experiment Video

Updated: Jun 17, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

Comment on 'Huntington's disease presenting as ALS'

Jessica Mandrioli, Chiara Bernabei, Eleni Georgoulopoulou

    Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases
    |December 17, 2009
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
    15:48

    ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

    Published on: July 29, 2007

    Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells
    11:12

    Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells

    Published on: October 4, 2017

    Related Experiment Videos

    Last Updated: Jun 17, 2026

    Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
    07:08

    Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

    Published on: February 27, 2018

    ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
    15:48

    ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

    Published on: July 29, 2007

    Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells
    11:12

    Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells

    Published on: October 4, 2017